PLGA is the second most common intraoral malignant salivary gland tumor, preferentially affecting the minor salivary glands 1 . This tumor occasionally originates in other anatomical sites, including the lungs and breast 2 . PLGAs are characterized by cytological uniformity and histological diversity 1 . Despite their infiltrative growth pattern and tendency for perineural invasion, PLGAs have a relatively indolent clinical course, with lymph node metastasis in up to 29% of cases and rare distant metastasis 3, 4 . Owing to the large spectrum of histological appearances of PLGAs, the differentiation of these tumors from more aggressive forms of salivary gland cancer is challenging, especially in small diagnostic specimens.
Recent studies have demonstrated that distinct types of malignant salivary gland tumors, including adenoid cystic carcinoma (AdCC), mucoepidermoid carcinoma and secretory carcinoma, are driven by specific highly recurrent somatic genetic alterations (for example, fusion genes) 5 . Like PLGA, these tumor types can also originate in other anatomical sites, including the lungs and breast 2 . We therefore reasoned that PLGA might be driven by a highly recurrent somatic genetic alteration.
To test this hypothesis, we subjected three consecutive PLGAs to massively parallel RNA sequencing and whole-exome sequencing and a separate set of three PLGAs to whole-exome sequencing (Supplementary Table 1 ). RNA sequencing did not identify any recurrent in-frame fusion genes (Supplementary Table 2 ). By contrast, whole-exome sequencing identified two somatic heterozygous single-nucleotide variants (SNVs) in the PRKD1 gene, c.2130A>T and c.2130A>C, affecting a highly conserved amino acid in the catalytic loop (Fig. 1a) and resulting in the same amino acid substitution, p.Glu710Asp, in five of six cases (Fig. 1b, Supplementary  Fig. 1 and Supplementary Table 1 ). RNA sequencing demonstrated that the mutant alleles were expressed ( Supplementary Fig. 2 and Supplementary Table 1) . No additional recurrent somatic SNVs or insertion-deletions (indels) were detected (Supplementary Table 3) . We therefore subjected a validation cohort of 53 PLGAs to Sanger sequencing and targeted amplicon sequencing of PRKD1 exon 15 and confirmed the presence of the somatic c.2130A>T and c.2130A>C mutations in 41.5% and 30.2% of PLGAs, respectively (Fig. 1b,  Supplementary Fig. 3 and Supplementary Table 4 ). In total, 43 of 59 (72.9%) PLGAs tested harbored a PRKD1 mutation encoding p.Glu710Asp. Detailed pathological analysis of PLGAs with mutated and wild-type PRKD1, however, did not identify distinct histological features that would differentiate the two groups (data not shown). PLGAs with and without the PRKD1 mutation encoding p.Glu710Asp were found to express PRKD1 protein (Fig. 1c and 
Supplementary
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands Fig. 2b,c) , suggesting that, as with other mutation-activated oncogenes 6 , the expression of PRKD1 protein is more pervasive than the presence of a PRKD1 hotspot mutation.
PRKD1 is a serine-threonine kinase that has a role in cell adhesion, cell migration, vesicle transport and cell survival 7 . We found that the PRKD1 gene was mutated in 2.2% of the cancer samples included in The Cancer Genome Atlas (TCGA) and other published data sets available on cBioPortal 8 , but none of these cancers harbored the PRKD1 c.2130A>T or c.2130A>C (p.Glu710Asp) mutations, suggesting that these SNVs might be unique to PLGA (Fig. 1d,e) . In addition, these new PRKD1 mutations have not been reported in the Catalog of Somatic Mutations in Cancer 9 (COSMIC, v68; data not shown). To determine whether the PRKD1 mutations encoding p.Glu710Asp would be pathognomonic for PLGA, we investigated the presence of these mutations in a series of 311 tumors of the salivary glands (186 malignant and 125 benign lesions), of which 12 were PLGAs. The PRKD1 mutations encoding p.Glu710Asp were found in eight of the PLGAs but not in any of the other salivary gland tumors studied ( Fig. 1f and Supplementary Table 5) . Therefore, our findings demonstrate that the PRKD1 hotspot mutations encoding p.Glu710Asp, akin to the CRTC1-MAML2 and MYB-NFIB fusion genes defining subsets of mucoepidermoid carcinoma and AdCC, respectively 5 , define a subset of PLGAs of the salivary glands and might be useful as an ancillary diagnostic marker to differentiate PLGAs from other forms of salivary gland tumors. In addition, the presence of a PRKD1 mutation encoding p.Glu710Asp was significantly associated with the metastasisfree survival of individuals with malignant salivary gland tumors (P = 0.027; Fig. 1g, Supplementary Table 6 and Supplementary Note), suggesting that these mutations might be useful in the molecular prognostic work-up of salivary gland cancers.
The p.Glu710Asp hotspot alteration affects the catalytic loop HCDLKPEN of the PRKD1 protein kinase domain (Fig. 1a) and was predicted to be pathogenic by independent mutation function assessment algorithms (Supplementary Table 3 ). Although the crystal structure of PRKD1 is not yet solved, homology modeling suggested that the p.Glu710Asp alteration could either interfere with ADP binding by altering coordination with Mg 2+ or affect enzyme kinetics, as it is positioned in between the ATP donor binding site and the putative proton acceptor (Fig. 2a and Supplementary Fig. 4a ). The glutamic acid residue is highly conserved among the CAMK kinases; however, an aspartic acid residue is frequently observed within the native structures of AGC kinases, suggesting that the identified alteration is likely active but might induce a functional shift (Supplementary ). Consistent with these protein structure predictions, in a cell-free in vitro kinase assay, p.Glu710Asp-mutant PRKD1 displayed significantly increased transphosphorylation of the serine-threonine substrate CREBtide and elevated autocatalytic activity in comparison to wild-type PRKD1 (P < 0.0001; Fig. 2b and Supplementary Fig. 5a ).
Forced expression of wild-type and p.Glu710Asp-mutant PRKD1 in embryonic kidney epithelial and non-malignant breast epithelial cell lines ( Supplementary Fig. 5b ) resulted in increased phosphorylation of Ser738/Ser742 within the activation loop and Ser910 in the autocatalytic site of the mutant PRKD1 protein relative to wild-type protein in all subcellular compartments ( Fig. 2c and Supplementary  Fig. 5c ), in agreement with the higher trans-and autocatalytic kinase activity detected in the cell-free kinase assay. Previous studies have suggested that PRKD1 activation reduces cell migration and invasion but promotes the growth of epithelial cells 7 . Consistent with this notion, forced expression of p.Glu710Asp-mutant PRKD1 in conventional in vitro models resulted in reduced cell migration, despite an increase in cell viability ( Supplementary  Fig. 6 ). To ascertain whether the PRKD1 hotspot mutations encoding p.Glu710Asp would affect the growth and glandular architecture of epithelial cells, we forced expression of wild-type and p.Glu710Asp-mutant PRKD1 in two non-malignant breast epithelial cell lines, MCF10A and MCF12A, grown in three-dimensional cultures 10 . These cells were chosen because PLGA cell lines and non-malignant models of minor salivary gland cells are not available and because, albeit rarely, primary PLGAs have been reported in the breast 2 . Forced expression of p.Glu710Asp-mutant PRKD1 changed the hollow spheroid, acinar-like structures formed by parental or empty vectortransfected MCF10A and MCF12A cells into larger, coalescent structures with filled lumens and irregular contours not uncommonly displaying infiltrating edges, a phenotype consistent with that induced by the forced expression of other oncogenes in this model system 10, 11 ( Fig. 2d) . Taken together, our findings demonstrate that the somatic PRKD1 hotspot mutations encoding p.Glu710Asp are likely activating and might confer a neoplastic advantage to epithelial cells.
We have identified somatic PRKD1 activating hotspot mutations encoding p.Glu710Asp in the majority of PLGAs, which might be employed as an ancillary molecular marker to differentiate PLGA from its more aggressive mimics, including AdCC. PRKD1 emerges as a new cancer-related gene, which likely constitutes a driver of PLGA and might be exploited as a diagnostic aid and therapeutic target. Our study emphasizes that investigating the genetic underpinnings of rare cancer types can lead to the identification of new oncogenic drivers and help in the development of a molecular taxonomy of cancers 12 .
URLs. cBioPortal, http://www.cbioportal.org/; Picard, http://picard. sourceforge.net/.
Methods
Methods and any associated references are available in the online version of the paper. 
oNLINe Methods

Subjects and samples. After obtaining institutional review board (IRB)
approval from the respective institutions of the authors, representative histological blocks of PLGAs were retrieved from the pathology archives of the respective pathology departments and sent to the pathology department of the University Health Network (UHN) (Toronto, Ontario, Canada) or Memorial Sloan-Kettering Cancer Center (MSKCC) (New York, New York, USA). In addition, three frozen samples of PLGAs and matched adjacent normal salivary gland samples were retrieved from the MSKCC Tumor Procurement Service, and three frozen samples of PLGAs were retrieved from the UHN Biospecimen Sciences Program.
Sixty-eight cases were reviewed by the contributing pathologists and centrally reviewed by two pathologists with an interest and expertise in head and neck cancer pathology (I.W. and B.P.-O.). Only cases classified as classic PLGA according to the World Health Organization definition were included in this study 1 . Cases that fulfilled the diagnostic criteria of cribriform adenocarcinoma of the minor salivary glands or adenocarcinoma not otherwise specified were excluded 1 . In total, 59 classic PLGAs were included in this study, six of which were fresh frozen and 53 of which were formalin fixed and paraffin embedded. Patient consents were obtained if required by the IRB protocols approved by each author's institution. Follow-up data were obtained from patient charts from the authors' institutions. Before tissue processing, samples were anonymized.
The discovery cohort (Supplementary Table 1 ) comprised six freshfrozen PLGAs, three of which had matched frozen adjacent normal salivary gland tissue available. These three cases with matched adjacent normal tissue were microdissected with a needle under a stereomicroscope as previously described 13 . RNA was extracted from microdissected tumor samples as previously described 13 and subjected to paired-end massively parallel RNA sequencing. DNA was extracted separately from microdissected tumor samples and normal adjacent tissues as previously described 13 and subjected to whole-exome sequencing. From the remaining three cases, only representative frozen tumor tissues were available; these cases were microdissected and DNA was extracted and subjected to whole-exome sequencing.
The validation cohort (Supplementary Table 4 ) consisted of representative formalin-fixed, paraffin-embedded samples from 53 PLGAs. These samples were microdissected with a needle under a stereomicroscope, and DNA was extracted and quantified and its quality assessed as previously described 13 .
For power calculations, assuming that, akin to other rare tumor types 14, 15 , PLGAs would be driven by a recurrent hotspot mutation or fusion gene present in ≥70% of cases, a binomial distribution showed that by sequencing six samples we would be able to identify a recurrent event (occurring in two or more cases) with >90% statistical power.
Paired-end massively parallel RNA sequencing and fusion gene identification. The three PLGAs retrieved from MSKCC were subjected to massively parallel RNA sequencing using a validated protocol 16 employed in the MSKCC Integrated Genomics Operation (iGO). In brief, paired-end RNA sequencing was performed with 2 × 75-bp cycles on the Illumina HiSeq 2000 platform. Data were aligned to the reference human genome hg19 using Bowtie 2 (ref. 17) . For PLGA_1, PLGA_2 and PLGA_3, 121.7, 66.7 and 56.8 million reads were obtained, respectively. Read pairs supporting fusion transcripts were identified using ChimeraScan (v0.4.5) 18 and deFuse (v0.6.1) 19 . To filter out common alignment artifacts and normal transcriptional variation, we removed fusion gene and read-through candidates that were also found in a set of 47 normal samples from TCGA (project 4767). Candidate fusions were annotated using Oncofuse 20 (Supplementary Table 2 ).
Whole-exome sequencing. For the MSKCC samples, microdissected tumor and germline DNA were subjected to exome capture with SureSelect Human All Exon v4 (Agilent Technologies) using a validated protocol 16 Variant calling. For the MSKCC samples, reads were aligned to the reference human genome hg19 using the Burrows-Wheeler Aligner (BWA, v0.6.2) 22 . Local realignment and quality score recalibration were performed using the Genome Analysis Toolkit (GATK, v3.1.1) 23 . Deduplication was performed using Picard (v1.92). Somatic SNVs were called using MuTect (v.1.1.4) 24 , and small somatic indels were called using VarScan2 (v2.3.6) 25 and the GATK HaplotypeCaller (v3.1.1) 23 . Variants found with >5% global minor allele frequency in dbSNP (Build 137) or that were supported by <5 reads were disregarded. SNVs for which the tumor variant allele fraction was <5 times than that of the normal variant allele fraction were disregarded. All indels were manually inspected using the Integrative Genomics Viewer (IGV) 26 .
For the UHN samples, reads were aligned to the UCSC build hg19 reference using Novoalign (v2.07.14, Novocraft Technologies). Alignments were optimized by soft clipping low-quality end positions and rescuing poorly aligned reads via high-quality anchoring of their fragment pair. SAMtools (v1.18) 27 was used for deduplication and filtering. Local realignment, quality score recalibration and variant detection were performed using GATK (v2.4.7) 23 , employing recommended best practices (v3 and v4). On-target variants (padded by 10 bp) were considered, and variants that were flagged by GATK base quality, read depth, alternate allele frequency and haplotype inconsistency filters were removed. Variants in dbSNP (Build 137; variants not flagged as somatic or clinical or as having a minor allele frequency of <1%; ref. 28) or in the 1000 Genomes Project (phase 1, release v3, 23 November 2010) were removed. Variants were excluded if they occurred in Fuentes 29 , ENCODE 30 or the Duplicated Gene Database 31 or in ten normal blood samples (data not shown). All COSMIC variants (v64) were white-listed 9, 32 .
Prediction of the functional effect of the mutations was performed using PolyPhen-2 (ref. 33) , MutationTaster 34 , Mutation Assessor 35 , FATHMM 36 , CHASM (breast, head and neck, and other classifiers) 37 , CanDrA (breast classifier) 38 and CADD 39 .
PCR amplification, Sanger sequencing and targeted amplicon sequencing.
The presence of somatic PRKD1 mutations encoding p.Glu710Asp was validated in all PLGAs from the discovery cohort and investigated in all PLGAs from the validation cohort by Sanger sequencing analysis of tumor and germline samples as previously described 40 . For this analysis, primers (Supplementary Table 7 ) to amplify a 338-bp fragment covering exon 15 of the PRKD1 gene (chromosomal position: chr. 14: 30,068,073-30,068,410) were designed using OligoPerfect (Life Technologies). PCR fragments were then purified using ExoSAP-IT (USB) and sequenced as previously described 40 .
For targeted amplicon sequencing, 5 ng of genomic DNA was amplified with primers specific for exon 15 of the PRKD1 gene (Supplementary Table 7 ) using a high-fidelity Taq polymerase (Roche). PCR amplicons were sequenced on a MiSeq instrument (Illumina) using 150 × 150 chemistry. Reads were aligned to the reference human genome hg19 using BWA (v0.6.2) 22 . Local realignment and quality score recalibration were performed using GATK (v3.1.1) 23 . Mutations were called using the GATK HaplotypeCaller (v3.1.1) 23 and were manually inspected using IGV 26 .
Immunohistochemistry. Representative sections from 3 frozen PLGAs included in the discovery set from MSKCC and from 18 formalin-fixed, paraffinembedded PLGAs from the validation cohort were cut at 4 µm and mounted npg on Superfrost Plus slides (Fisher Scientific). Frozen sections of each of the three tumors were briefly fixed in acetone and subjected to PRKD1 immunohistochemical analysis. Formalin-fixed, paraffin-embedded sections were subjected to heat-induced antigen retrieval using the pH 9 Target Retrieval Solution (Dako) at 92.8 °C for 20 min in a water bath, and immunohistochemical analysis was then performed using a polyclonal antibody to PRKD1 (Sigma-Aldrich, HPA029834; 1:250 dilution). Detection of bound antibody was performed using the ABC-diaminobenzidine method (Vector Laboratories). Negative controls (omission of the primary antibody and substitution of the primary antibody with IgG-matched control) and positive controls (formalin-fixed, paraffin-embedded pellets 41 of MCF12A cells transfected with empty vector or with vector for wild-type or p.Glu710Asp-mutant PRKD1) were included in each slide run. Sections were analyzed by two pathologists (C.M. and J.S.R.-F.) blinded to the PRKD1 mutation status of the cases using the H-score system, whereby cytoplasmic expression in histologically unequivocal neoplastic cells was semiquantitatively assessed. Nuclear expression was semiquantitatively assessed using the Allred scoring system as previously described 42 ; an Allred score of >2 was considered positive. Unequivocal membranous expression was not observed in any case. No statistically significant difference in the expression levels of cytoplasmic and nuclear PRKD1 was observed between PLGAs with mutant and wild-type PRKD1 (Supplementary Fig. 2c ). Table 5 ). DNA was extracted from all cases as described above. In 96-well plates, the DNA samples from these cases and 8 randomly selected PLGAs previously included in the validation series described above were assembled by 3 of the authors and subjected to Sanger sequencing as described above by another author, who was blinded to the identity and diagnosis of the samples and prior sequencing results.
To define the impact of the PRKD1 mutations encoding p.Glu710Asp on the outcome of patients with malignant salivary gland tumors, a cohort of malignant salivary gland tumors was retrospectively accrued by combining (i) all cases of malignant salivary gland tumors subjected to screening for the PRKD1 c.2130A>T and c.2130A>C (p.Glu710Asp) mutations with (ii) all cases of PLGA analyzed in this study. This combined data set comprised 237 individual patients. Follow-up data were obtained from patient charts reviewed by three of the authors. After follow-up data were obtained, samples were anonymized. Follow-up information was available for 149 patients with malignant salivary gland tumors, ranging from 1 to 180 months (median of 34 months; Supplementary Table 6 ). Metastasis-free survival was expressed as the number of months from diagnosis to the occurrence of distant relapse. Survival analysis was performed using SPSS version 20 (IBM). Cumulative survival probabilities were calculated using the Kaplan-Meier method. Differences between metastasis-free survival rates were tested with the log-rank test. A P value of <0.05 was considered significant.
Homology modeling.
A homology model of the kinase domain of PRKD1 and p.Glu710Asp-mutant PRKD1 was generated using SWISS-MODEL [43] [44] [45] [46] on the structure of CHEK2 (Protein Data Bank (PDB) 2YCR) with which it has 40% sequence identity (Supplementary Fig. 4a,b) . The model for the ADP molecule was obtained from a related CHEK2 structure (2CN5) with overlap generated by PyMOl (v1.5.0.4, Schrödinger). The homology models were evaluated using QMEAN [47] [48] [49] [50] (Supplementary Fig. 4a) . The QMEANnorm score and QMEAN z score 49 estimate the absolute quality of a homology model in comparison to X-ray crystallography reference structures. The reference structures are a non-redundant subset of PDB with less than 30% pairwise sequence identity among themselves and resolved at a resolution of <2 Å. PRKD1 models have QMEAN z scores of −1.80 (wild type) and −1.71 (mutant), resulting in a QMEANnorm score of 0.60 for both (Supplementary Fig. 4a ) and placing the models well within the range of scores for similarly sized resolved structures in the reference set. Residue-by-residue examination showed that the active site and mutation region (Supplementary Fig. 4a) were modeled with high accuracy. Model error was dominated by regions near flexible loops and toward the extremities of the homology model. All homology model visualizations are for one chain in the dimer and were rendered using the Visual Molecular Dynamics software suite 51 .
Sequence alignment and analysis of the PRKD1 mutant site against the human protein kinase complement. Multiple-Sequence Comparison by Log Expectation (MUSCLE) 52 was used to align the mutated kinase domain of PRKD1 against an alignment of the eukaryotic protein kinase (ePK) domains used in Manning et al. 53 describing the major kinase groups. All sequences observed to display a glutamic acid or aspartic acid at the homologous site of the PRKD1 alteration were identified and used in conjunction with Kinomerender 54 Cell lines. MCF10A, MCF12A, HEK293T and NIH3T3 cells were purchased from the American Type Culture Collection (ATCC), authenticated using short tandem repeat profiling as previously described 40 and tested for mycoplasma using the PCR-based Universal Mycoplasma Detection kit (ATCC). All cell lines were maintained in an atmosphere with 5% CO 2 at 37 °C. MCF10A and MCF12A cells were cultured in DMEM/F12 supplemented with 5% horse serum, 20 ng/ml epidermal growth factor (EGF), 10 µg/ml insulin, 0.5 µg/ml hydrocortisone and 1% penicillin-streptomycin as described in ref. 10 , and HEK293T and NIH3T3 cells were cultured in DMEM high glucose supplemented with 10% FBS and 1% penicillin-streptomycin.
Vector construction, mutagenesis, transformation and plasmid preparation. The human PRKD1 (NM_002742) cDNA clone was purchased from Origene (RG211676; C-terminal TurboGFP tag). The mutation encoding p.Glu710Asp was introduced in pCMV6:PRKD1-tGFP using the Q5 Site-Directed Mutagenesis kit (New England BioLabs). The presence of the correct mutation and the absence of rearrangements were confirmed by Sanger sequencing (primer sequences available in Supplementary Table 7) .
Transfections of mammalian cells and analysis of transgene expression.
Transfections with plasmids were performed using Lipofectamine LTX and PLUS Reagent (Life Technologies) following the manufacturer's guidelines. The expression of transgenes was visually evaluated 48 h after transfection using a Nikon Eclipse Ti fluorescence inverted microscope and by protein blotting using antibodies to PRKD1/PKCµ (see below).
Protein blotting. Standard protein blotting was conducted as previously described 40 
